Xcovry Holding

Xcovery is a clinical-stage biopharmaceutical company focused on developing next-generation targeted therapies for the treatment of cancer. The company's lead program, ensartinib (X-396), is a potent and selective ALK inhibitor that has been approved in China for ALK-positive non-small cell lung cancer and has undergone global Phase 3 evaluation. Xcovery's pipeline also includes vorolanib (X-82), an oral multi-kinase inhibitor targeting VEGFR and PDGFR for oncology and ophthalmology indications. Founded by the lead inventor of sunitinib, the company leverages deep expertise in kinase inhibitor chemistry to address unmet medical needs. Xcovery operates as a subsidiary of Betta Pharmaceuticals, utilizing a collaborative model to advance its candidates through international clinical development.